Veterinary Orthobiologics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product (Stem Cells, Platelet-rich Plasma (PRP), Other), By Animal (Canine, Equine, Others), By Application (Osteoarthritis, Degenerative Joint Disease, Other), By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others), By End User (Veterinary Hospitals, Veterinary Clinics, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 787.27 Million
CAGR (2026-2031)	8.89%
Fastest Growing Segment	Platelet-Rich Plasma (PRP)
Largest Market	North America
Market Size (2031)	USD 1312.36 Million

Market Overview

The Global Veterinary Orthobiologics Market will grow from USD 787.27 Million in 2025 to USD 1312.36 Million by 2031 at a 8.89% CAGR. Veterinary orthobiologics are biological substances such as platelet-rich plasma, stem cells, and bone grafts that veterinarians utilize to repair injured bones, ligaments, and tendons while regenerating tissue. The primary drivers fueling market expansion include the rising incidence of osteoarthritis in aging companion animals and the increasing willingness of owners to invest in premium healthcare services. This heightened demand for advanced medical intervention is reflected in substantial industry spending. According to the American Pet Products Association, in 2024, United States veterinary care and product sales reached 39.8 billion dollars. This financial commitment supports the continued adoption of regenerative therapies.

However, the market confronts a notable impediment regarding the high costs associated with these treatments. Many orthobiologic procedures remain prohibitively expensive for average pet owners, and the lack of comprehensive insurance coverage for regenerative therapies in certain regions further limits accessibility. Consequently, financial constraints represent a significant challenge that could restrict the widespread implementation of these solutions and dampen overall market growth velocity.

Key Market Drivers

The increasing prevalence of veterinary orthopedic and musculoskeletal disorders, significantly exacerbated by rising pet obesity rates, serves as a primary catalyst for market growth. As companion animals carry excess weight, the mechanical stress on joints intensifies, leading to a higher incidence of osteoarthritis and ligament injuries that require regenerative interventions. According to the Association for Pet Obesity Prevention, April 2025, in the '2024 Pet Obesity & Nutrition Opinion Survey', 35% of dog owners and 33% of cat owners classified their pets as overweight or obese, marking a concerning year-over-year increase. This upward trajectory in weight-related health issues directly correlates with the surging demand for orthobiologic therapies, such as platelet-rich plasma and stem cells, which offer effective management for chronic joint deterioration.

Simultaneously, the rising trend of pet humanization and companion animal ownership is fundamentally reshaping the economic landscape of veterinary care. Owners increasingly view their pets as integral family members, driving a willingness to pursue advanced, often costly, medical treatments to ensure their longevity and quality of life. According to the American Pet Products Association, March 2025, in the '2025 State of the Industry Report', pet ownership has expanded remarkably, with 94 million U.S. households now owning at least one pet. This growing base of dedicated owners provides the necessary market scale for continued investment in novel regenerative technologies. Illustrating this rapid sector innovation, according to Gallant Therapeutics, July 2025, the company secured 18 million dollars in Series B funding to accelerate the commercialization of its off-the-shelf stem cell therapies, highlighting the robust financial confidence in the future of veterinary orthobiologics.

Download Free Sample Report

Key Market Challenges

The prohibitive cost of treatment constitutes a substantial impediment to the growth of the veterinary orthobiologics sector. These regenerative therapies often involve complex processing and specialized application, resulting in high prices that are typically passed directly to the pet owner. Since veterinary healthcare in many major markets operates largely on a fee-for-service basis, these substantial out-of-pocket expenses frequently render such options inaccessible to the average client. This financial reality effectively restricts the addressable market to a narrow demographic of affluent pet owners, preventing the volume of procedures necessary to drive rapid industry expansion.

This economic hurdle is heavily exacerbated by the limited penetration of pet health insurance, which fails to bridge the affordability gap for most households. Without comprehensive coverage to offset expenses, the market struggles to transition from niche usage to mass adoption. According to the North American Pet Health Insurance Association, in 2025, the total number of insured pets in North America reached 7.03 million. This figure indicates that the vast majority of owners lack the financial safety net required to fund premium regenerative procedures, directly dampening market volume and revenue velocity.

Key Market Trends

The market is witnessing a major Shift Toward Allogeneic "Off-the-Shelf" Stem Cell Therapies, driven by the urgent need for scalable, standardized treatments for common inflammatory diseases. Unlike autologous methods that require surgical extraction and processing, these manufactured therapies offer immediate availability and consistent dosing, addressing high-volume clinical needs in general practice. This demand is significantly underscored by the prevalence of difficult-to-treat conditions that require advanced intervention; according to DVM360, July 2025, in the article 'Veterinary stem cell therapy advances toward FDA approval with $18M in funding', refractory feline chronic gingivostomatitis alone affects up to 26% of domestic cats, creating a substantial addressable market for these novel, ready-to-use regenerative solutions.

Simultaneously, there is a marked Expansion of Regenerative Medicine in Equine Sports Performance, where orthobiologics are becoming standard protocols for managing athletic injuries. High-value performance horses require rapid, effective recovery strategies for tendon and ligament issues, prompting specialized veterinary centers to integrate these therapies into their core services to extend competitive careers. Highlighting this rising adoption rate within elite facilities, according to VetStem, October 2025, in the press release 'Tryon Equine Hospital Surpasses 200 VetStem Regenerative Medicine Cases', a single leading equine referral center successfully completed over 200 regenerative procedures, signaling a broader industry acceptance and the commercial viability of these treatments in the equine sector.

Segmental Insights

The Platelet-Rich Plasma segment represents the fastest growing category within the global veterinary orthobiologics market. This expansion is primarily driven by the rising prevalence of osteoarthritis in companion animals and a corresponding shift toward minimally invasive management strategies. Veterinary practitioners favor these autologous treatments due to their cost-effectiveness and the operational efficiency of point-of-care preparation. Furthermore, the introduction of FDA-cleared concentration systems has standardized clinical outcomes, thereby enhancing practitioner confidence in safety and efficacy. Consequently, the combination of therapeutic accessibility and regulatory assurance continues to fuel the rapid adoption of this segment.

Regional Insights

North America maintains a leading position in the Global Veterinary Orthobiologics Market, primarily driven by the rising prevalence of orthopedic disorders such as osteoarthritis among a growing companion animal population. This dominance is supported by substantial expenditure on animal healthcare and a well-established veterinary infrastructure that facilitates access to regenerative therapies. Furthermore, the presence of major industry participants actively developing new treatments strengthens the regional market. The regulatory environment, overseen by institutions such as the U.S. Food and Drug Administration, provides structured pathways for product approval, thereby fostering a stable climate for commercial expansion.

Recent Developments

• In October 2025, PetVivo Animal Health, Inc. entered into a vendor partner agreement with Veterinary Growth Partners to expand the commercial reach of its veterinary medical devices. The collaboration focuses on promoting the company's flagship products, including its proprietary intra-articular injectable and a platelet-rich plasma system, to a network of over 7,300 veterinary members. This partnership aims to accelerate the adoption of these restorative therapies by making them more accessible to clinics seeking non-pharmaceutical options for managing joint-related conditions. The agreement highlights the increasing integration of orthobiologic solutions into standard veterinary practice management groups.
• In June 2025, Gallant secured $18 million in a Series B financing round to advance its pipeline of "off-the-shelf" stem cell therapies for companion animals. The investment was led by Digitalis Ventures and included participation from new partners with expertise in human allogeneic cell therapy. The company stated that the capital would be utilized to finalize the development and seek conditional FDA approval for its leading therapeutic candidate, which targets feline chronic gingivostomatitis. Furthermore, the funding is intended to support the expansion of the company's platform to address other widespread conditions, such as osteoarthritis in dogs and cats.
• In April 2025, Creative Science announced the acquisition of Astaria Global, a company recognized for its specialized orthobiologic therapies in the equine health sector. This strategic transaction was executed to strengthen the acquiring company’s portfolio in veterinary pain management and regenerative medicine. Astaria Global had established a strong market presence with its science-driven products designed to address inflammation and support soft tissue healing in horses. The acquisition allows for the broader distribution of these advanced therapeutic solutions, reflecting a growing industry trend toward consolidating innovative regenerative technologies to improve accessibility for veterinary practitioners.
• In May 2024, VetStem, Inc. announced the launch of a new equine-specific orthobiologic product following the completion of a review by the U.S. Food and Drug Administration. The company introduced PrecisePRP Equine, a leukoreduced, allogeneic, pooled, freeze-dried platelet-rich plasma designed for intra-articular administration in horses. This product creates a consistent dose of platelets for veterinarians without the need for blood draws or centrifugation equipment. The FDA indicated that the product aligns with its risk-based approach to regulating animal cell and tissue-based products, marking it as the first FDA-reviewed platelet-rich plasma option available for equine use.

Key Market Players

• Zoetis Services LLC
• Boehringer Ingelheim International GmbH
• Ardent Animal Health
• Enso Discoveries, LLC
• VetStem, Inc
• MEDREGO LLC
• Arthrex, Inc.
• Hilltop Biosciences
• Enovis Corporation
• Dechra Pharmaceuticals Limited

By Product	By Animal	By Application	By Delivery Mode	By End User	By Region
Stem Cells Platelet-rich Plasma (PRP) Other	Canine Equine Others	Osteoarthritis Degenerative Joint Disease Other	Intra-muscular/Intra-lesional Intra-articular Others	Veterinary Hospitals Veterinary Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Orthobiologics Market, By Product:

• Stem Cells
• Platelet-rich Plasma (PRP)
• Other

• Veterinary Orthobiologics Market, By Animal:

• Canine
• Equine
• Others

• Veterinary Orthobiologics Market, By Application:

• Osteoarthritis
• Degenerative Joint Disease
• Other

• Veterinary Orthobiologics Market, By Delivery Mode:

• Intra-muscular/Intra-lesional
• Intra-articular
• Others

• Veterinary Orthobiologics Market, By End User:

• Veterinary Hospitals
• Veterinary Clinics
• Others

• Veterinary Orthobiologics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE